Toronto, Ontario--(Newsfile Corp. - August 6, 2025) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative care, is pleased to announce the Company will release its Fiscal Second Quarter 2025 financial results for the period ended June 30, 2025, on Wednesday, August 13, 2025. The Company will hold a conference call and simultaneous webcast to discuss its results on the same day at 1:00 pm ET (10:00 am PT). The call will be hosted by James Lee, Chief Executive Officer, Dr. Alexander Dobranowski, President and Anthony Lam, Chief Financial Officer.
HEALWELL AI Fiscal Second Quarter 2025 Financial Results Conference Call
Date: Wednesday, August 13, 2025
Time: 1:00 PM ET / 10:00 AM PT
Webcast link: https://www.gowebcasting.com/14139
Toll-Free North America: 1-833-752-3509
International Toll: 1-647-846-7993
When connecting to the conference call via phone, please dial in 10 minutes prior to the start of the call and ask to be joined into the "HEALWELL AI Inc. Conference Call."
James Lee
Chief Executive Officer
HEALWELL AI Inc.
About HEALWELL AI
HEALWELL is a healthcare artificial intelligence company focused on preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary technology, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the Company's road map. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol "AIDX" and on the OTC Exchange under the symbol "HWAIF". To learn more about HEALWELL, please visit https://healwell.ai/.
For more information:
Pardeep S. Sangha
Investor Relations, HEALWELL AI Inc.
Phone: 604-572-6392
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | C$0.95 |
| Daily Change: | -0.02 -2.06 |
| Daily Volume: | 419,400 |
| Market Cap: | C$264.480M |
November 06, 2025 November 03, 2025 September 25, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
